40 GUEST STREET, BOSTON, MA
Investor Presentation
CFO Appointment - James Ahlers Named Chief Financial Officer
Announces $50.0 Million Private Placement
Stockholders Approve 2026 Stock Incentive Plan at Special Meeting
Material disclosure
Reports First Quarter 2026 Financial Results and Recent Strategic Developments
Expands Pipeline with Exclusive License for Clinical-Stage Dual-Mechanism Anti-IgE Antibody
Q1
FY 2025
Q3
Q2
FY 2024
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Amended Statement of Changes in Beneficial Ownership
Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Submission Upload
Correspondence